RADIOMEDIX
GenericsRADIOMEDIX is a generic drug manufacturer focused on Oncology. Key products include GALLIUM GA 68 GOZETOTIDE.
RADIOMEDIX's Key Drugs
RADIOMEDIX's core commercial portfolio centers on GALLIUM GA 68 GOZETOTIDE, spanning Oncology — its most strategically important drugs approved in the last 15 years.
RADIOMEDIX's Recent FDA Approvals
New NDA/BLA approvals for RADIOMEDIX over the last two years — novel drugs only, excluding generics and label supplements.
RADIOMEDIX's Therapeutic Areas
RADIOMEDIX's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RADIOMEDIX's Top Competitors
RADIOMEDIX's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
RADIOMEDIX Pipeline Snapshot
RADIOMEDIX has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GALLIUM GA 68 GOZETOTIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2026-06-08
- Latest
- 2026-06-08
- Applications
- 1